Carbon dioxide is considered one of the most significant contributors to climate change. Current data from the U.S. Environmental Protection Agency shows that greenhouse gasses like methane, carbon dioxide, and nitrous oxide have increased significantly since just before the Industrial Revolution. Carbon dioxide is currently at 40% higher concentrations thanks to human activities that release 30 billion tons of it into the atmosphere annually.
As a result, many researchers are devoting their time to unpacking how the world can reduce and combat carbon emissions. One tactic used so far is to utilize carbon dioxide in a productive way for industrial processes like enhanced oil recovery, food processing, carbonated beverages, and as a solvent in several industries.
For several decades innovative products have shown that the potential uses of captured CO₂ are endless, including in the healthcare industry.
D’OXYVA on Climate Change
Circularity Healthcare is an emerging multinational leader in noninvasive transdermal and circulatory health technologies. It is the company behind the patented transdermal delivery system, D’OXYVA.
D’OXYVA works to improve blood circulation, which is incredibly helpful for the diabetic community. The use of the vapor has shown a reduction in amputations and a clear decline in chronic pain for its users.
Circularity and D’OXYVA state, “Our goal is to educate people about this powerful modality’s groundbreaking evidence and science. It is currently undergoing pivotal clinical trials with the involvement of 18 of the 20 top-ranked U.S. universities for becoming an FDA-approved universal treatment for severe diabetic lower extremity complications and amputation prevention.” They add to this by arguing, “By funding and utilizing carbon capture directly from industry and the atmosphere and turning that CO² into FDA-approved pharmaceutical products, we can make a significant dent in reducing unwanted carbon-induced climate change.”
Ideally, climate change requires a transition to green energy, but until then, putting the carbon produced by industries into use reduces the problem significantly.
Creating Advanced and Noninvasive Treatments From CO²
Last year, Circularity Healthcare announced its contract with the Professional Educational Research Institute (PERI) for a new clinical trial of D’OXYVA on diabetic patients in several U.S. university hospitals. The regulatory approvals obtained from the Western Institutional Review Board (WIRB) were faster than that seen in competing products in the last few decades.
PERI’S CEO, Dr. Charles M. Zelen, said on its clinical efficacy, “Thousands of competing products in the past twenty-five years have failed in achieving what D’OXYVA® has obtained regarding regulatory authorizations, clinical safety, and effectiveness in the past seven years.”
Studies have shown better oxygen and blood circulation throughout the organs and tissues with a five-minute delivery of D’OXYVA to the thumb several times a day. Besides diabetics, the treatment shows promising relief for several other conditions, including arthritis, chronic pain, fibromyalgia, burns, trauma and chronic wounds, athletic performance, and vascular diseases, including erectile dysfunction.
Outcomes from several studies in several countries have shown that 97% of users experienced relief and circulation benefits from D’OXYVA’s groundbreaking solution.
The topical non-prescription spray takes just five minutes to apply, and the number of applications depends on the severity of the condition. Typically, the patient needs two or three daily applications at the start. Then, as they see an improvement in their situation, they can minimize the daily dosage and use it a few times a week.
Application delivery is typically done on the thumb but can also occur on any affected body part. Other significant benefits of the fast-acting regenerative technology of D’OXYVA include improved sleep quality, increased stamina and cognition, and mood enhancement.
As part of their battle to educate people about innovative work around CO² in pharmaceutical products, people can look forward to upcoming journal publications on D’OXYVA and other significant benefits. These include the promising studies on transdermal CO² that have also recently emerged, where it appears to suppress ischemia-reperfusion injury in surgeries requiring temporary abdominal aorta cross-clamping.
Final Take
Circularity Healthcare has more than one mission. Improving lives by improving blood flow is their first, but they also have a deep commitment to fighting the causes and effects of climate change. As they continue to educate people about the importance of improving blood flow with oxygenated tissue in their microcirculation and promoting a healthier lifestyle, they also continue to support the efforts of global organizations to find ways to deal with CO² effectively until we transition into a cleaner world.
